Wesley Research Institute
Donate
Now

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement.

Research Objectives

Status

Current

Recruitment

Open

Estimated completion

December 2023

Patient Group

Patients undergoing total knee replacement surgery (arthroplasty)

Total Participants

80

Study location

Wesley Research Institute, Griffith University

Study type

Investigator Initiated
find out if you’re eligible

Lead investigator

  • A/Prof Susan Clark

Experienced investigator

  • Prof Robert Ware

Clinical trial coordinator

  • Emma Craig

Technical title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty (TXA002)

About this research project

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement. The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of you needing a blood transfusion and may decrease pain, swelling and recovery time following the operation. Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about the best dosing of the drug to achieve optimal patient outcomes. This study will assess whether different treatment durations will lead to better results for patients.

Latest News & Discoveries

Breakthrough Research Reveals Why Some Cancer Patients Respond to Immunotherapy While Others Don’t

In a groundbreaking study, Australian researchers at the Queensland Spatial Biology Centre (QSBC) have uncovered a crucial factor that determines whether patients with head and neck cancer will respond to immunotherapy - a finding that could pave the way for more effective treatments and improved survival rates.  

New Research Highlights the Potential of Private Virtual Hospitals to Improve Healthcare Access 

New research has revealed the immense potential of private virtual hospitals to transform healthcare delivery in Australia.  The study explores how these “hospitals without walls” can safely and effectively provide hospital-level care in patients’ homes, combining telehealth consultations, remote monitoring, and hybrid care approaches.

Wesley Research Institute’s First Coeliac Disease Webinar Series A Success

Wesley Research Institute’s inaugural Coeliac Disease Webinar Series has been met with an overwhelming response. The two-session event - one tailored for individuals living with coeliac disease and the other for clinicians - featured leading experts Dr James Daveson, Clinical Director of the Coeliac Research and Immune Health Program at Wesley Research Institute, and Dr Jason W. Chien, Chief Medical Officer at Mozart Therapeutics.
1 2 3 19
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram